Dal, M. S. Et Al. 2023. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey. ANNALS OF HEMATOLOGY , vol.102, no.1 , 133-140.

Dal, M. S., Ulu, B. U., UZAY, A., Akay, O. M., Besisik, S., Yenerel, M. N., ... ÇELİK, S.(2023). Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey. ANNALS OF HEMATOLOGY , vol.102, no.1, 133-140.

Dal, Mehmet Et Al. "Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey," ANNALS OF HEMATOLOGY , vol.102, no.1, 133-140, 2023

Dal, Mehmet S. Et Al. "Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey." ANNALS OF HEMATOLOGY , vol.102, no.1, pp.133-140, 2023

Dal, M. S. Et Al. (2023) . "Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey." ANNALS OF HEMATOLOGY , vol.102, no.1, pp.133-140.

@article{article, author={Mehmet Sinan Dal Et Al. }, title={Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey}, journal={ANNALS OF HEMATOLOGY}, year=2023, pages={133-140} }